The stock has shown some stability over the last few weeks but it needs to do more so that it can resume its uptrend. The correction after the earnings took it from the highs to the crucial supports. Fundamentally, the company needs to show improvement in the bottom-line margins consistently. Currently, the ttm revenue is $83 million and the net loss is around $9.2 million. In a recent interview Brad Pyatt, the CEO, was particularly confident about the possibilities related to the Arnold range, and also the product range for women. MusclePharm is one of the few companies which covers all the product categories for women. The company plans to put the female fitness products into some larger retailers like Walgreen (WAG), GNC Holdings(GNC) and CVS Caremark (CVS) whose buyers are 70% women. Topline growth has never been a problem for MusclePharm as the company has grown exponentially over the years. This year it is on course to touch $100 million in revenues. Brad mentioned the support of Dr. Frost who helped change the capital structure of the company. Dr. Frost helped bring the sophisticated institutional investor interest which has helped the company get rid of the toxic debt. MusclePharm recently invested in one of Dr. Frost's companies Biozone (BZNE). Biozone is into contract manufacturing and also has a patented drug deliver technology (QuSomes) which can help reduce manufacturing costs significantly. This investment can help the company in improving margins in the long run. Most importantly, Brad expects the balance sheet cleanups to be completed in 2014, and a full EBIDTA-type profit without any derivative liabilities associated. It will be great if the company can get to a net profit as that would change the outlook significantly. Even the expected listing on NASDAQ will have a long-term profound effect on the stock.